William D. Hanley

Statistics

Publications

Citations

2.3K

H-Index

Active since

1960

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Johns Hopkins University

Seagen (United States)

Genmab (United States)

Prism Clinical Research

William D. Hanley is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, pharmacokinetics, and clinical pharmacology.

Publications per year

1960–2024

Publications

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

Robert L. Avery, Alessandro Castellarin, Nathan Steinle et al. · Retina · 2017 · 341 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +17

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

Peter A. Campochiaro, Dennis M. Marcus, Carl C. Awh et al. · Ophthalmology · 2019 · 269 citations · Full text

Pharmacy, Ophthalmology, Pharmacotherapy +17

Single Molecule Characterization of P-selectin/Ligand Binding

William D. Hanley, Owen J. T. McCarty, Sameer Jadhav et al. · Journal of Biological Chemistry · 2003 · 179 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +17

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

Larissa Wenning, William D. Hanley, Diana M. Brainard et al. · Antimicrobial Agents and Chemotherapy · 2009 · 160 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

CD44 on LS174T Colon Carcinoma Cells Possesses E-Selectin Ligand Activity

William D. Hanley, Monica M. Burdick, Robert Sackstein · Cancer Research · 2005 · 135 citations · Full text

Life Sciences, Cell Biology, Oncology +17

1–5 of 32